Newsfeeds - Spark Newswire

5 minute read

The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering

Today, 2:08 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)

ACAD

6 minute read

84 Biggest Movers From Friday

By Lisa Levin

Today, 2:08 AM

Gainers

ACOR

4 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 2:08 AM

Before 10 a.m. ET Friday, 51 stocks hit new 52-week lows.

ACAD

1 minute read

Needham Maintains Buy on Zogenix, Lowers Price Target to $44

By Benzinga Newsdesk

Today, 2:08 AM

Needham analyst Serge Belanger maintains Zogenix (NASDAQ:ZGNX) with a Buy and lowers the price target from $48 to $44.

ZGNX

1 minute read

SVB Leerink Maintains Outperform on Zogenix, Lowers Price Target to $37

By Benzinga Newsdesk

Today, 2:08 AM

SVB Leerink analyst Marc Goodman maintains Zogenix (NASDAQ:ZGNX) with a Outperform and lowers the price target from $42 to $37.

ZGNX

1 minute read

Earnings

Shares of Zogenix (NASDAQ:ZGNX) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 9.38% year over year to ($1.05), which missed the estimate of ($0.94).

ZGNX

1 minute read

Zogenix Q2 EPS $(1.05) Misses $(0.94) Estimate, Sales $18.79M Beat $17.08M Estimate

By Benzinga Newsdesk

Today, 2:08 AM

Zogenix (NASDAQ:ZGNX) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.94) by 11.7 percent. This is a 9.38 percent decrease over losses of $(0.96) per share from the same

ZGNX

34 minute read

Earnings Scheduled For August 5, 2021

By Benzinga Insights

Today, 2:08 AM

Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

AAOI

1 minute read

Zogenix Highlights Recognition Of FINTEPLA In Epilepsy & Behavior Editorial

By Bill Haddad

Today, 2:08 AM

Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that its product FINTEPLA® (fenfluramine) oral solution has been recognized by two

ZGNX

7 minute read

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street

By Shanthi Rexaline

Today, 2:08 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19)

ABIO

Latest news

The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering

84 Biggest Movers From Friday

Stocks That Hit 52-Week Lows On Friday

Needham Maintains Buy on Zogenix, Lowers Price Target to $44

SVB Leerink Maintains Outperform on Zogenix, Lowers Price Target to $37

Recap: Zogenix Q2 Earnings

Zogenix Q2 EPS $(1.05) Misses $(0.94) Estimate, Sales $18.79M Beat $17.08M Estimate

Earnings Scheduled For August 5, 2021

Zogenix Highlights Recognition Of FINTEPLA In Epilepsy & Behavior Editorial

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street